Dynamic Analysis of Ca 125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer As A Predictor for Sensitivity to Platinum

Aim: Our objective was evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum. Materials and Methods: Patients diagnosed between 2002 and 2009, and treated with NAC and interval debulking surgery, were included in the study, Results: One hundred and forty-two patients met the study inclusion criteria. Fifty-four patients (38%) were platinum-sensitive (PEI >12 months). A CA125 level after the 3rd NAC cycle <35 Mul was significantly associated with improved overall survival (OS) and relapse free survival (RT'S). In the multivariate model, patients with a CA125 level after the 3rd NAC cycle >35 Ulm( were 3.8-times more at risk for PH <12 months (95% p<0.001), Conclusion: A CA125 level after the 3rd NAC <35 Uinta is an independent predictor for tumor platinum-sensitivity.